PureTech Health plc (NASDAQ:PRTC - Get Free Report) was the target of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 8,100 shares, a decrease of 22.1% from the April 30th total of 10,400 shares. Approximately 0.0% of the company's shares are short sold. Based on an average daily trading volume, of 5,200 shares, the short-interest ratio is currently 1.6 days.
Institutional Trading of PureTech Health
Institutional investors and hedge funds have recently bought and sold shares of the stock. Birch Hill Investment Advisors LLC purchased a new position in shares of PureTech Health during the fourth quarter valued at approximately $5,575,000. Pentwater Capital Management LP grew its position in shares of PureTech Health by 39.2% during the 1st quarter. Pentwater Capital Management LP now owns 33,560 shares of the company's stock valued at $664,000 after acquiring an additional 9,449 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of PureTech Health during the 4th quarter valued at $823,000. 0.04% of the stock is currently owned by hedge funds and other institutional investors.
PureTech Health Stock Up 2.5%
Shares of PRTC traded up $0.47 during trading hours on Thursday, hitting $19.07. The company had a trading volume of 138 shares, compared to its average volume of 4,677. The stock's 50 day moving average price is $17.25 and its 200 day moving average price is $18.56. PureTech Health has a 52-week low of $13.30 and a 52-week high of $29.80.
About PureTech Health
(
Get Free Report)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Recommended Stories
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
